Kymera Therapeutics (KYMR) Operating Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has reported Operating Expenses for 8 consecutive years, with $118.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Expenses rose 22.78% year-over-year to $118.5 million; the TTM figure through Mar 2026 stood at $410.6 million (up 21.8% YoY), while the FY2025 annual figure was $388.6 million, up 25.88% from the prior year.
• Operating Expenses rose to $118.5 million in Q1 2026 per KYMR's latest filing, from $100.8 million in the prior quarter.
• Across five years, Operating Expenses topped out at $118.5 million in Q1 2026 and bottomed at $46.6 million in Q1 2022.
• Historically, Operating Expenses has averaged $74.6 million across 5 years, with a median of $68.1 million in 2024.
• On a YoY basis, Operating Expenses climbed as much as 46.07% in 2022 and fell as far as 11.15% in 2022.
• Kymera Therapeutics' Operating Expenses stood at $54.8 million in 2022, then grew by 22.69% to $67.2 million in 2023, then jumped by 31.18% to $88.1 million in 2024, then climbed by 14.31% to $100.8 million in 2025, then grew by 17.62% to $118.5 million in 2026.
• Business Quant data shows KYMR's Operating Expenses at $118.5 million in Q1 2026, $100.8 million in Q4 2025, and $95.3 million in Q3 2025.